Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury (Epis-AKI)

July 18, 2022 updated by: University Hospital Muenster

The evaluation of an accurate occurrence rate for AKI is of great importance for health policy, quality initiatives as well as for designing clinical trials.

The primary objective is to prospectively evaluate the incidence of AKI within 72 h after extended surgical procedures that require admission to an observation unit.

Study Overview

Status

Completed

Detailed Description

Acute kidney injury (AKI) is a severe clinical complication with increasing incidence and is associated with adverse short- and long-term outcomes resulting in a major health care burden worldwide. The introduction of consensus classification systems has enhanced the awareness for AKI. The evaluation of an accurate occurrence rate for AKI is of great importance for health policy, quality initiatives as well as for designing clinical trials. However, analyzing AKI from existing databases is often limited by missing data elements, especially the inclusion of the urine output criteria. Missing data and the use of different definitions before the consensus classification are the reasons for large variations in reported occurrences of surgical induced AKI.

The primary objective is to prospectively evaluate the incidence of AKI within 72 h after extended surgical procedures that require admission to an observation unit (e.g., Intensive Care Unit, Intermediate Care, Post Anesthesia Care Unit) using the latest consensus definition for AKI (Kidney Disease: Improving Global Outcomes criteria) and a standardized data collection instrument and to assess the dependence of AKI on preoperative and intraoperative factors.

Method: International prospective, observational, multi-center, cross-sectional cohort study

Eligible patients will be identified during preoperative assessment. All eligible patients will be approached to obtain written consent.

Study Type

Observational

Enrollment (Actual)

10568

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Alexandria, Egypt
        • Alexandria University
      • Mansoura, Egypt
        • Mansoura University Hospitals
      • Tanta, Egypt
        • Tanta University Faculty of medicine
      • Angers, France
        • CHU d'Angers
      • Blois, France
        • Centre Hospitalier Simone Veil de Blois
      • Bordeaux, France
        • CHU de Bordeaux
      • Caen, France
        • Centre de Lutte Contre le Cancer François Baclesse
      • Cesson-Sévigné, France
        • Hôpital Privé Sévigné
      • Lille, France
        • Hôpital Huriez - CHU de Lille
      • Limoges, France
        • Clinique Chenieux
      • Lyon, France
        • Hôpital Edouard Herriot
      • Morlaix, France
        • Centre hospitalier des pays de Morlaix
      • Nice, France
        • CHU de Nices
      • Paris, France
        • Hôpital Bichat
      • Reims, France
        • Hopital Maison Blance
      • Strasbourg, France
        • Clinique Sainte-Anne
      • Tarbes, France
        • CHG Tarbes
      • Toulouse, France
        • Clinique Pasteur Toulouse
      • Vantoux, France
        • Hôpital Robert Schuman-Groupe UNEOS
      • Villejuif, France
        • Gustave Roussy
      • Muenster, Germany, D-48149
        • University Hospital Muenster
      • Mönchengladbach, Germany
        • Kliniken Maria Hilf
      • Münster, Germany, 48165
        • Herz Jesu Krankenhaus Münster Hiltrup
      • Sendenhorst, Germany, 48324
        • St. Josef-Stift Sendenhorst
      • Tübingen, Germany
        • Universitätsklinikum Tübingen
      • Montebelluna, Italy
        • Ospedale di Montebelluna
      • Palermo, Italy
        • University of Palermo
      • Potenza, Italy
        • Cardioanestesia - Azienda Ospedaliera San Carlo di Potenza
      • Rome, Italy
        • Ospedale Sant'Eugenio di Roma
      • Tripoli, Libyan Arab Jamahiriya
        • National Heart Center Tripoli
      • Tripoli, Libyan Arab Jamahiriya
        • Tripoli Central Hospital
      • Birkirkara, Malta, MSD-2090
        • Mater Dei Hospital
      • Skopje, North Macedonia
        • University Clinic
      • Gaza City, Palestinian Territory, occupied
        • Al-Shifa Medical Complex
      • Hebron, Palestinian Territory, occupied
        • Alia Governmental Hospital
      • Kemerovo, Russian Federation
        • Kemerovo Cardiology Centre
      • Moscow, Russian Federation
        • Bakulev Scientific Center for Cardiovascular Surgery
      • Saint Petersburg, Russian Federation
        • Polenov Neurosurgical Institute
      • Khobar, Saudi Arabia
        • Almana General Hospital
      • Ljubljana, Slovenia, SI-2000
        • University Medical Centre Maribor
      • Murska Sobota, Slovenia
        • Splosna bolnisnica Murska Sobota
      • Alava, Spain
        • Hospital Universitario Araba
      • Alcorcón, Spain
        • Hospital Universitario Funcacion Alcorcón
      • Barcelona, Spain
        • Urology Fundación Puigvert
      • Donostia, Spain
        • Donostia University Hospital
      • Granada, Spain
        • Hospital Cliínico Universitario Virgen de las Nieves
      • Las Palmas De Gran Canaria, Spain
        • Hospital Universitario de Gran Canaria Doctor Negrín
      • Logroño, Spain
        • San Pedro Hospital
      • Madrid, Spain
        • Hospital Ramon y Cajal
      • Madrid, Spain
        • Hospital Universitario 12 de Octubre
      • Madrid, Spain
        • Infanta Leonor University Hospital
      • Palma De Mallorca, Spain
        • Son LLatzer University Hospital
      • Adana, Turkey
        • Çukurova university
      • Akdeniz, Turkey
        • Akdeniz University Hospital
      • Ankara, Turkey
        • Ankara City Hospital
      • Ankara, Turkey
        • Ibn Sina Hospital
      • Ankara, Turkey
        • Kahramanmaras Sutcu Imam University
      • Balıkesir, Turkey
        • Balikesir University
      • Bursa, Turkey
        • Uludag University
      • Bursa, Turkey
        • University of Health Sciences
      • Derince, Turkey
        • Health Sciences University Medical School
      • Düzce, Turkey
        • Duzce University
      • Gazi, Turkey
        • Gazi University Hospital
      • Istanbul, Turkey
        • Istanbul University
      • Istanbul, Turkey
        • İstanbul University - Cerrahpaşa
      • Istanbul, Turkey
        • Koc University Hospital
      • Istanbul, Turkey
        • Acibadem MAA Ünv. Altunizade Ä'Acibadem
      • Istanbul, Turkey
        • Acibadem MAA Ünv. Atakent Acibadem
      • Istanbul, Turkey
        • Haseki Egitim Arastirma
      • Istanbul, Turkey
        • Prof. Dr. Cemil Tascioglu City Hospital
      • Istanbul, Turkey
        • Yeditepe
      • Kartal, Turkey
        • Health Sciences University Kartal
      • Malatya, Turkey
        • Inönü University Hospital
      • Manisa, Turkey
        • Manisa, Medical Faculty
      • Merkez, Turkey
        • Suleyman Demirel University School of Medicine
      • Mersin, Turkey
        • Mersin University
      • Samsun, Turkey
        • Mayis University
      • Trabzon, Turkey
        • Karadeniz Technical University
      • Trakya, Turkey
        • University Faculty of Medicine
      • İzmir, Turkey
        • Dokuz Eylul Universitesi
      • İzmir, Turkey
        • Izmir Democracy University School of Medicine
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Adult patients undergoing extended surgical procedure and the need for postoperative observation

Description

Inclusion Criteria:

  • major elective or emergency surgery procedures with a duration of at least 2 h
  • admission to the intensive care unit, intermediate care unit after surgery informed consent

Exclusion Criteria:

  • preexisting acute kidney injury
  • acute kidney injury within the last 3 months
  • end stage renal disease with dialysis dependency
  • kidney transplant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with extended surgical exposures
Patients with extended surgical exposures requiring postoperative observation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Acute Kidney Injury
Time Frame: 72 hours after extended surgery
Occurrence of acute kidney injury according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria
72 hours after extended surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of acute kidney injury (number of patients with KDIGO stage 1, KDIGO stage 2 or KDIGO stage 3)
Time Frame: 72 hours after extended surgery
Definition and classification of acute injury according to the KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines on acute kidney injury
72 hours after extended surgery
Number of patients with renal replacement therapy
Time Frame: up to 90 days after extended surgery
up to 90 days after extended surgery
Mortality
Time Frame: up to 90 days after extended surgery
up to 90 days after extended surgery
Hospital stay
Time Frame: up to 90 days after extended surgery (until discharge)
up to 90 days after extended surgery (until discharge)
Intensive Care Unit stay
Time Frame: up to 90 days after extended surgery (until discharge)
up to 90 days after extended surgery (until discharge)
Major Adverse Kidney Events (MAKE)
Time Frame: up to 90 days after extended surgery
combined endpoint consisting of mortality, renal replacement therapy, persistent renal dysfunction defined as serum-creatinine >= 1.5 times as compared to baseline serum-creatinine
up to 90 days after extended surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Alexander Zarbock, MD, PhD, University Hospital Muenster, Dept. of Anesthesiology, Intensive Care and Pain Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 9, 2020

Primary Completion (ACTUAL)

February 28, 2022

Study Completion (ACTUAL)

March 31, 2022

Study Registration Dates

First Submitted

October 30, 2019

First Submitted That Met QC Criteria

November 13, 2019

First Posted (ACTUAL)

November 18, 2019

Study Record Updates

Last Update Posted (ACTUAL)

July 21, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 01-AnIt-19

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury (AKI)

3
Subscribe